Q-omics provides the consensus-scored SNHG16 profile across patient tissues and cancer cell-line models. SNHG16 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SNHG16 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, SNHG16 RNA expression shows 19,367 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, COAD, and ACC as cancer lineages where SNHG16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNHG16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNHG16 survival associations across molecular data types. SNHG16 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNHG16 RNA expression–survival associations across cancer types. High SNHG16 expression shows unfavorable associations in KIRP, ACC, BLCA, LIHC and UCEC, but favorable associations in UVM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SNHG16 RNA expression.
This table summarizes SNHG16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SNHG16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNHG16 shows higher tumor expression in COAD, HNSC, KIRC, KIRP, LIHC and READ. The COAD box plot shows higher SNHG16 RNA expression in tumor versus normal tissue (log2 FC = +1.563, t-test p < 0.001).
This table shows molecular features associated with SNHG16 in patient tissues and cancer cell lines. In patient samples, SNHG16 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
